CLINICAL_TRIALS
trial_result
· 2013-10-22
Clinical Trial Update: A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects [Phase 1]
Summary
A Phase 1, double-blind, randomized controlled study in CD20-positive diffuse large B-cell lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: DLBCL | Phase 1 | Status: COMPLETED